3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
114
Neoplasms
28
Lung Neoplasms
24
Non-Squamous Non-Small Cell Lung Cancer
21
Pancreatic Neoplasms
13
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lymphoma
3
Thoracic Neoplasms
2
Solid Tumors
2
Recurrence
2
Neoplasms by Site
2
Lung Diseases
2
Familial ependymoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Bronchial Neoplasms
2
Advanced Solid Tumors
2
Vascular Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoking
1
Small Cell Lung Carcinoma
1
Interventions
pembrolizumab
74
Carboplatin
45
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Bevacizumab
9
eribulin
8
Cisplatin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled